癌症诊断药相关的联盟和授权合约 (2016～2024年)

本报告提供癌症诊断药相关的近来 (2016～2024年) 的联盟授权合约趋势相关分析，彙整整体交易数量的转变，及财务方面 (付款条件) 的倾向，由于主要企业 (全25公司) 的交易形成的动向，契约条件的倾向，各技术详细内容趋势等调查，近几年主要的联盟交易内容等详细资讯，为您概述为以下内容。

目录

摘要整理

第1章 简介

第2章 癌症诊断药相关的交易形成的倾向

• 简介
• 癌症诊断药相关交易的长期趋势
• 癌症诊断药相关最活跃的交易业者
• 癌症诊断药相关的交易:各交易类型
• 癌症诊断药相关的交易:各治疗领域
• 癌症诊断药相关的交易:各业界
• 癌症诊断药相关的交易:交易条件
  • 癌症诊断药相关的交易:交易总额
  • 癌症诊断药相关的交易:预付款金
  • 癌症诊断药相关的交易:阶段性付款
  • 癌症诊断药相关的交易:使用费率

第3章 癌症诊断药相关的主要交易

• 简介
• 癌症诊断药相关的主要的交易:以契约金额为准

第4章 用癌症诊断药相关最活跃的交易企业

• 简介
• 癌症诊断药相关交易上最活跃的企业
• 癌症诊断药相关交易上最活跃的企业:简介

第5章 癌症诊断药相关的契约缔结一览

• 简介
• 癌症诊断药相关的契约缔结一览

第6章 癌症诊断药相关的交易:各技术种类

• 交易一览
• 交易一览:癌症诊断药相关，各企业 (ABC顺序)
• 交易一览:癌症诊断药相关，各交易类型
• 交易一览:癌症诊断药相关，各治疗领域
• 交易的种类定义
• 关于Biopharma Research Ltd
• 目前联盟
• 目前契约
• Current Partnering出版的最近报告标题

Cancer Diagnostic Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the cancer diagnostic deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of cancer diagnostic deals from 2016 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter cancer diagnostic deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 846 cancer diagnostic deals announced since 2016 including financial terms where available including links to online deal records of actual cancer diagnostic partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of cancer diagnostic dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in cancer diagnostic dealmaking since 2016.

Chapter 3 provides an overview of the leading cancer diagnostic deals since 2016. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in cancer diagnostic dealmaking with a brief summary followed by a comprehensive listing of cancer diagnostic deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of cancer diagnostic deals signed and announced since Jan 2016, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of cancer diagnostic partnering deals signed and announced since Jan 2016. The chapter is organized by specific cancer diagnostic technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in cancer diagnostic deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Cancer Diagnostic Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse cancer diagnostic collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Cancer Diagnostic Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of cancer diagnostic trends and structure of deals entered into by leading biopharma companies worldwide.

Cancer Diagnostic Collaboration and Licensing Deals includes:

• Trends in cancer diagnostic dealmaking in the biopharma industry
• Directory of cancer diagnostic deal records covering pharmaceutical and biotechnology
• The leading cancer diagnostic deals by value
• Most active cancer diagnostic licensing dealmakers
• Cancer Diagnostic Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in cancer diagnostic dealmaking

• 2.1. Introduction
• 2.2. Cancer diagnostic deals over the years
• 2.3. Most active cancer diagnostic dealmakers
• 2.4. Cancer diagnostic deals by deal type
• 2.5. Cancer diagnostic deals by therapy area
• 2.6. Cancer diagnostic deals by industry sector
• 2.7. Deal terms for cancer diagnostic deals
  • 2.7.1 Cancer diagnostic deals headline values
  • 2.7.2 Cancer diagnostic deal upfront payments
  • 2.7.3 Cancer diagnostic deal milestone payments
  • 2.7.4 Cancer diagnostic royalty rates

Chapter 3 - Leading cancer diagnostic deals

• 3.1. Introduction
• 3.2. Top cancer diagnostic deals by value

Chapter 4 - Most active cancer diagnostic dealmakers

• 4.1. Introduction
• 4.2. Most active cancer diagnostic dealmakers
• 4.3. Most active cancer diagnostic deals company profiles

Chapter 5 - Cancer diagnostic contracts dealmaking directory

• 5.1. Introduction
• 5.2. Cancer diagnostic contracts dealmaking directory

Chapter 6 - Cancer diagnostic dealmaking by technology type

• Deal directory
• Deal directory - Cancer diagnostic deals by company A-Z
• Deal directory - Cancer diagnostic deals by deal type
• Deal directory - Cancer diagnostic deals by therapy area
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Cancer diagnostic deals since 2016
• Figure 2: Active cancer diagnostic dealmaking activity - 2016 - 2024
• Figure 3: Cancer diagnostic deals by deal type since 2016
• Figure 4: Cancer diagnostic deals by therapy area since 2016
• Figure 5: Cancer diagnostic deals by industry sector since 2016
• Figure 6: Cancer diagnostic deals with a headline value
• Figure 7: Cancer diagnostic deals with an upfront value
• Figure 8: Cancer diagnostic deals with a milestone value
• Figure 9: Cancer diagnostic deals with a royalty rate value
• Figure 10: Top cancer diagnostic deals by value since 2016
• Figure 11: Most active cancer diagnostic dealmakers 2016 - 2024
• Figure 12: Cancer diagnostic deals by technology type since 2016